Oral antiplatelet therapy and percutaneous coronary intervention

Author： Yan Bryan PY   Clark David J   Ajani Andrew E  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.6, Iss.1, 2005-01, pp. : 3-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents

By  

Current Clinical Pharmacology, Vol. 8, Iss. 1, 2013-02 ,pp. : 59-66

Bentham Science Publishers

Access to resources Recommend Favorite

Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes

By Jennings Lisa K  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 1, Iss. 4, 2005-12 ,pp. : 727-737

Informa Healthcare

Access to resources Recommend Favorite

Antiplatelet Agents in Patients Undergoing Percutaneous Coronary Intervention: How Many and How Much?

By Duffy Brendan   Bhatt Deepak L.  

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 5, 2005-01 ,pp. : 307-318

Adis International

Access to resources Recommend Favorite

Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention

By Heeg Bart M.S.  

PharmacoEconomics, Vol. 25, Iss. 9, 2007-01 ,pp. : 769-782

Adis International

Access to resources Recommend Favorite

Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention

By  

Current Pharmaceutical Design, Vol. 22, Iss. 29, 2016-09 ,pp. : 4604-4609

Bentham Science Publishers

Access to resources Recommend Favorite